Svetlana Eckert, MD
Neurology · Buffalo, NYNPI 1477998060
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,693 of the $123,636 with a category attached, or 79.8%. EMD Serono, Inc. accounts for 67.3% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $72,719, more than ten times the $1,705 reported in 2019. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $376.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$83K
- TG Therapeutics, Inc.$26K
- Merck$7K
- Genentech USA, Inc.$4K
- Biogen$1K
- Amgen$665
- plus $2K from 15 others
Across 1 payment — averaging $1983.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
What the payments were for
- Consulting fees$11,4139%
- Speaking & faculty fees$98,69380%
- Travel & lodging$4,6144%
- Food & beverage$8,4267%
- Education$4900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 79 | $83,237 |
| TG Therapeutics, Inc. | 29 | $25,562 |
| Merck | 10 | $7,142 |
| Genentech USA, Inc. | 77 | $4,135 |
| Biogen | 40 | $1,360 |
| Amgen(2 entities) | 46 | $665 |
| Novartis | 7 | $437 |
| Pfizer | 14 | $234 |
| Bristol Myers Squibb | 7 | $219 |
| AstraZeneca | 3 | $169 |
| Greenwich Biosciences, Inc. | 1 | $110 |
| Genentech, Inc. | 2 | $92 |
| AbbVie | 2 | $51 |
| CSL Behring | 2 | $45 |
| Sanofi | 3 | $45 |
| Eisai Inc. | 1 | $33 |
| SK Life Science, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Argenx US, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$123,636 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 61 | $550,813 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 59 | $379,870 |
| CopaxoneGlatiramer Acetate | 48 | $307,321 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 36 | $306,721 |
| VumerityDiroximel Fumarate | 24 | $242,683 |
| Teriflunomide | 69 | $230,048 |
| RebifInterferon Beta-1a/Albumin | 15 | $218,413 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 16 | $164,068 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 27 | $143,651 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $95,796 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $72,420 |
| GlatopaGlatiramer Acetate | 12 | $47,371 |
| Dalfampridine ErDalfampridine | 125 | $43,809 |
| Glatiramer Acetate | 20 | $36,480 |
| SunosiSolriamfetol Hcl | 14 | $22,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $24 | $379,87059 claims |
| BiogenVumerity | $1,360 | $242,68324 claims |
| EMD Serono, Inc.Rebif | $83,237 | $218,41315 claims |
| PfizerOctagam | $234 | $143,65127 claims |
| CSL BehringHizentra | $45 | $95,79611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Buffalo
- Gil WolfeBuffalo$617K
- David HojnackiBuffalo$480K
- Bianca Weinstock GuttmanBuffalo$288K
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.